Anguk Pharmaceuticals and Daewoo Pharmaceutical Collaborate on Dry Eye Syndrome Treatment Development... Targeting 2024 Launch

Executive Director Lee Oksun of Daewo Pharmaceutical (left) and Executive Director Chae Heeseong of Anguk Pharmaceutical (right) are posing for a commemorative photo after signing a joint development contract for ophthalmic treatments.
[Photo by Anguk Pharmaceutical]

[Asia Economy Reporter Lee Gwan-ju] Anguk Pharm and Daewoo Pharmaceutical recently announced on the 18th that they have signed a joint development agreement for ophthalmic treatments.

Anguk Pharm will jointly develop an eye dryness treatment being developed by Daewoo Pharmaceutical. This eye dryness treatment is a transparent eye drop that improves eye irritation and medication adherence, and research and development is being accelerated with the goal of market launch in 2024.

In April, Anguk Pharm began sales of the medical device 'VUNO Med-Fundus AI,' which applies artificial intelligence (AI) new medical technology for fundus examination interpretation. Along with this, they have solidified their position in the ophthalmology field by launching the eye nutrition health functional food 'Tobicom.'

An Anguk Pharm official stated, "Through this joint development agreement for ophthalmic treatments with Daewoo Pharmaceutical, we will do our best to ensure that Anguk Pharm successfully establishes itself in the ophthalmic treatment market."

This content was produced with the assistance of AI translation services.